The Novo Nordisk A/S line shows up 37 times in the congressional disclosure record between 2015 and 2026, filed by 16 members: 30 purchases against 7 sales. On balance the chamber has been net buyers, and the purchases sit down 55.0% against the latest close.
*Purchases only, weighted by the midpoint of each disclosed dollar band and marked to the latest close. Filings report a range, never a share count, so this follows the stock rather than anyone's position size.
Reported a NVO purchase in filings from the last 90 days, newest first. 1 member.
Members ranked by how their reported NVO purchases have moved since, over roughly the last three years, weighted by disclosed band midpoint and marked to the latest close.
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2026-09-10 | Kevin Hern | SELL | $1K–$15K | $44.01 | $39.13 2026-10-26 | +11.1% exit |
| 2026-08-31 | Kevin Hern | SELL | $1K–$15K | $45.33 | $39.13 2026-10-26 | +13.7% exit |
| 2026-08-26 | Scott Scott Franklin | BUY | $1K–$15K | $47.19 | $39.13 2026-10-26 | -17.1% |
| 2026-03-30 | Alan Armstrong | BUY | $15K–$50K | $35.29 | $39.13 2026-10-26 | +10.9% |
| 2025-10-15 | Marjorie Taylor Greene | BUY | $1K–$15K | $56.72 | $39.13 2026-10-26 | -31.0% |
| 2025-09-11 | Lisa McClain | BUY | $1K–$15K | $54.30 | $39.13 2026-10-26 | -27.9% |
| 2025-08-28 | Marjorie Taylor Greene | BUY | $1K–$15K | $56.11 | $39.13 2026-10-26 | -30.3% |
| 2025-08-19 | Marjorie Taylor Greene | BUY | $15K–$50K | $54.78 | $39.13 2026-10-26 | -28.6% |
| 2025-08-04 | Scott Scott Franklin | BUY | $15K–$50K | $48.81 | $39.13 2026-10-26 | -19.8% |
| 2025-08-04 | Scott Scott Franklin | BUY | $1K–$15K | $48.81 | $39.13 2026-10-26 | -19.8% |
| 2025-05-08 | Laurel Lee | SELL | $1K–$15K | $64.85 | $39.13 2026-10-26 | +39.7% exit |
| 2025-03-27 | Scott Scott Franklin | BUY | $15K–$50K | $70.16 | $39.13 2026-10-26 | -44.2% |
| 2025-03-27 | Scott Scott Franklin | BUY | $1K–$15K | $70.16 | $39.13 2026-10-26 | -44.2% |
| 2024-04-24 | Michael T. McCaul | BUY | $50K–$100K | $126.16 | $39.13 2026-10-26 | -69.0% |
| 2024-04-24 | Michael T. McCaul | BUY | $50K–$100K | $126.16 | $39.13 2026-10-26 | -69.0% |
| 2024-04-23 | Michael T. McCaul | BUY | $50K–$100K | $128.64 | $39.13 2026-10-26 | -69.6% |
| 2024-04-23 | Michael T. McCaul | BUY | $100K–$250K | $128.64 | $39.13 2026-10-26 | -69.6% |
| 2024-01-19 | Thomas H Tuberville | SELL | $15K–$50K | $106.96 | $39.13 2026-10-26 | +63.4% exit |
| 2022-10-07 | Byron Donalds | BUY | $1K–$15K | $52.03 | $39.13 2026-10-26 | -24.8% |
| 2021-09-16 | Katherine M. Clark | SELL | $1K–$15K | $51.19 | $39.13 2026-10-26 | +23.6% exit |
| 2020-11-09 | David P. Roe | BUY | $1K–$15K | $33.97 | $39.13 2026-10-26 | +15.2% |
| 2020-04-02 | Thomas R Carper | BUY | $1K–$15K | $29.66 | $39.13 2026-10-26 | +31.9% |
| 2020-04-02 | Thomas R Carper | BUY | $1K–$15K | $29.66 | $39.13 2026-10-26 | +31.9% |
| 2019-03-11 | Shelley M Capito | SELL | $1K–$15K | $24.87 | $39.13 2026-10-26 | -57.3% exit |
| 2017-09-08 | Shelley M Capito | BUY | $1K–$15K | $23.98 | $39.13 2026-10-26 | +63.1% |
| 2017-07-12 | David P. Roe | BUY | $1K–$15K | $21.43 | $39.13 2026-10-26 | +82.6% |
| 2016-12-21 | Charles J. "Chuck" Fleischmann | SELL | $1K–$15K | $17.70 | $39.13 2026-10-26 | -121.1% exit |
| 2016-09-28 | James B. Renacci | BUY | $1K–$15K | $21.87 | $39.13 2026-10-26 | +78.9% |
| 2016-09-23 | James B. Renacci | BUY | $1K–$15K | $22.44 | $39.13 2026-10-26 | +74.4% |
| 2016-06-23 | James B. Renacci | BUY | $1K–$15K | $26.70 | $39.13 2026-10-26 | +46.5% |
| 2016-06-22 | James B. Renacci | BUY | $1K–$15K | $26.21 | $39.13 2026-10-26 | +49.3% |
| 2016-05-31 | James B. Renacci | BUY | $1K–$15K | $28.02 | $39.13 2026-10-26 | +39.6% |
| 2016-05-25 | James B. Renacci | BUY | $1K–$15K | $28.15 | $39.13 2026-10-26 | +39.0% |
| 2016-05-24 | James B. Renacci | BUY | $15K–$50K | $27.48 | $39.13 2026-10-26 | +42.4% |
| 2016-05-24 | James B. Renacci | BUY | $1K–$15K | $27.48 | $39.13 2026-10-26 | +42.4% |
| 2015-10-22 | James B. Renacci | BUY | $1K–$15K | $26.82 | $39.13 2026-10-26 | +45.9% |
| 2015-09-15 | Robert J. Wittman | BUY | $1K–$15K | $28.06 | $39.13 2026-10-26 | +39.5% |
Buys are marked to the latest close and treated as open. A sell tagged rt closes an earlier disclosed buy in the same name. exit shows how the stock moved after the member sold.
16 members of the U.S. House and Senate have disclosed Novo Nordisk A/S transactions under the STOCK Act — 30 purchases and 7 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
1 member disclosed a NVO purchase in the last 90 days — most recently Scott Scott Franklin on 2026-08-26. See the "Lawmakers who bought NVO recently" section above for the dated list.
Notional-weighted, lawmakers' disclosed NVO buys are down 55.0% versus the latest close of $39.13. Each trade's own return — and realized round-trips on matched sells — is in the Return column.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded NVO and how it performed.